Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The 336 merged reexam decision

For the reexam to commence the examiner has to find some prior art that was probably cited by the requestor of the reexam. That was already told to the patent owner and filed by the original examiner when the order for reexam went out. They know what items are on the request for reexam already as far as prior art is concerned...if any.

Share
New Message
Please login to post a reply